article_snippet.sent: Scientists at the hospital combined a standard drug already used, ipilimumab, with another, nivolumab.
article_snippet.sent: the patient was given the patient first dose of ipilimumab and nivolumab, without complaining of any side effects.
article_snippet.sent: Patients were randomly assigned to receive ipilimumab and nivolumab or ipilimumab plus a placebo.
article_snippet.sent: Those selected to receive ipilimumab with a placebo to start with, were later allowed to receive nivolumab if the first drug was ineffective.
article_snippet.sent: In a staggering 61 per cent of patients receiving the combination therapy, Researchers at the Memorial Sloan-Kettering Cancer Center found significant tumour shrinkage.
article_snippet.sent: That was compared to just 11 per cent of the patients receiving ipilimumab plus a placebo.
article_snippet.sent: Patients receiving both drugs also lived longer without Patients receiving both drugs disease progressing.
article_snippet.sent: The study found 61 per cent of those treated with ipilimumab and nivolumab showed signs of ipilimumab and nivolumab tumours shrinking .
article_snippet.sent: But the side effects experienced by the patients on the combination therapy were worse, though the patients were still manageable.
article_snippet.sent: More research is still needed, however, to know if More research is necessary to give all patients this combination, or if patients should receive drugs like nivolumab and ipilimumab in sequence.'
article_snippet.sent: The US Food and Drug Administration approved nivolumab late last year.
highlights_snippet.sent: Combined standard drug ipilimumab with new drug nivolumab .
  